Active and treatment-refractory rheumatoid arthritis (RA)
KYTXKyverna TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for KYV-101 in Active and treatment-refractory rheumatoid arthritis (RA). The expected timing is based on the latest available company guidance and may change.
IIT trial. 10/24/25– Presented data at ACR’25. Ph2 portion enrollment completed. 03/26/26:- Phase 2 IIT rheumatoid arthritis data expected in 2026. 05/12/26:- PR No update. 06/03/26:- COMPARE Ph1 RA data updated at EULAR 2026. Ph2 initiated and fully enrolled. 08/11/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.